Список литературы

Поставить закладку

Bessler M. et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. // EMBO J. 1994. Vol. 13, № 1. P. 110–117.
Takeda J. et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria // Cell. 1993. Vol. 73, № 4. P. 703–711.
Medof B.Y.M.E., Kinoshita T., Nussenzweig V. INHIBITION OF COMPLEMENT OF CELLS AFTER ACTIVATION ON THE OF INCORPORATION ( DAF ) INTO THEIR MEMBRANES A key step in complement activation on targets is the deposition of C4b and / or C3b fragments . These major cleavage products of C3 and C4 can associa // J. Exp. Med. 1984. Vol. 160, № November. P. 1558–1578.
Lublin D.M., Atkinson J.P. Decay-Accelerating Factor: Biochemistry, Molecular Biology, and Function // Annu. Rev. Immunol. 1989. Vol. 7, № 1. P. 35–58.
Rollins S.A., Sims P.J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. // J. Immunol. 1990. Vol. 144, № 9. P. 3478 LP – 3483.
Noris M., Remuzzi G. Overview of complement activation and regulation // Semin. Nephrol. Elsevier, 2013. Vol. 33, № 6. P. 479–492.
Tegla C.A. et al. Membrane attack by complement: the assembly and biology of terminal complement complexes // Immunol. Res. 2011. Vol. 51, № 1. P. 45–60.
Serna M. et al. Structural basis of complement membrane attack complex formation // Nat. Commun. Nature Publishing Group, 2016. Vol. 7. P. 1–7.
Sun X. et al. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting // Proc. Natl. Acad. Sci. U. S. A. 1999. Vol. 96, № 2. P. 628–633.
Brodbeck W.G. et al. Structure/function studies of human decay-accelerating factor // Immunology. 2000. Vol. 101, № 1. P. 104–111.
Farkas I. et al. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9 // J. Physiol. 2002. Vol. 539, № 2. P. 537–545.
Bessler M., Hiken J. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuria. // Hematology Am. Soc. Hematol. Educ. Program. 2008. P. 104–110.
Hill A., Kelly R.J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria // Blood. 2013. Vol. 121, № 25. P. 4985–4996.
Rother R.P. et al. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin // JAMA. 2005. Vol. 293, № 13. P. 1653.
Olsen S.B. et al. Enhancement of Platelet Deposition by Cross-Linked Hemoglobin in a Rat Carotid Endarterectomy Model // Circulation. 1996. Vol. 93, № 2. P. 327–332.
Simionatto C.S. et al. Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers // Am. J. Med. 1988. Vol. 85, № 4. P. 538–540.
Studt J.-D. et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin // Blood. 2005. Vol. 105, № 2. P. 542–544.
Seregina E.A. et al. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria // Blood Cells, Mol. Dis. 2015. Vol. 54, № 2. P. 144–150.
Ritis K. et al. A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways // J. Immunol. 2006. Vol. 177, № 7. P. 4794–4802.
Wojta J. et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils // Blood. 2002. Vol. 100, № 2. P. 517–523.
Yu F., Du Y., Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America // Int. J. Hematol. Springer Japan, 2016. Vol. 103, № 6. P. 649–654.
Hill A. et al. Paroxysmal nocturnal haemoglobinuria // Nat. Rev. Dis. Prim. 2017. Vol. 3, № 1. P. 17028.
Hill A. et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. // Blood. 2006. Vol. 108, № September 2018. P. Abstract 985.
Кулагин А.Д. et al. Клиническая манифестация и ошибки диагностики классической пароксизмальной ночной гемоглобинурии : анализ 150 наблюдений Clinical Manifestation and Errors in the Diagnosis of Classical Paroxysmal Nocturnal Hemoglobinuria : A case series of 150 patients. 2017. Vol. 10, № 3. P. 333–341.
Hillmen P. et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria // Am. J. Hematol. 2010. Vol. 85, № 8. P. 553–559.
Hill A. et al. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: Raised pulmonary pressure and reduced right ventricular function // Br. J. Haematol. 2012. Vol. 158, № 3. P. 409–414.
Sahin F. et al. Pesg PNH diagnosis , follow-up and treatment guidelines. 2016. Vol. 6, № 2. P. 19–27.
Brodsky R.A. Paroxysmal nocturnal hemoglobinuria // Blood. 2014. Vol. 124, № 18. P. 2804–2811.
Кулагин А.Д. et al. Национальные клинические рекомендации по диагностике и лечению пароксизмальной ночной гемоглобинурии // Онкогематология. 2014. Vol. 2. P. 20–28.
Borowitz M.J. et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry // Cytom. Part B - Clin. Cytom. Wiley-Liss Inc., 2010. Vol. 78, № 4. P. 211–230.
Manivannan P., Ahuja A., Pati H.P. Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances // Indian J. Hematol. Blood Transfus. Springer India, 2017. Vol. 33, № 4. P. 453–462.
Movalia M.K. et al. Incidence of PNH Clones by Diagnostic Code Utilizing High Sensitivity Flow Cytometry // Blood. 2011. Vol. 118, № 21. P. 1033–1033.
Sipol A.A. et al. An inter-laboratory comparison of PNH clone detection by high-sensitivity flow cytometry in a Russian cohort // Hematology. 2015. Vol. 20, № 1. P. 31–38.
Dezern A.E., Borowitz M.J. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 – clinical utility // Cytom. Part B - Clin. Cytom. 2018. Vol. 94, № 1. P. 16–22.
Sutherland D.R. et al. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 – reagent selection and assay optimization for high-sensitivity testing // Cytom. Part B - Clin. Cytom. 2018. Vol. 94, № 1. P. 23–48.
Brubaker L.H., Essig L.R.J., Mengel C.E. Neutrophil life span in paroxysmal nocturnal hemoglobinuria // Blood. 1977. Vol. 50, № 4. P. 657–662.
Patriquin C.J. et al. How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry // European Journal of Haematology. Blackwell Publishing Ltd, 2019. Vol. 102, № 1. P. 36–52.
Бокерия Л.А., Затевахин И.И., Кириенко А.И. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). // Флебология. 2015. Vol. 4, № 2. P. 3–52.
Villegas A. et al. Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria // Med. Clin. (Barc). Ediciones Doyma, S.L., 2016. Vol. 146, № 6. P. 278e1-278e7.
Hill A. et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria // Blood. 2005. Vol. 106, № 7. P. 2559–2565.
Hillmen P. et al. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria // N. Engl. J. Med. 2006. Vol. 355, № 12. P. 1233–1243.
Savva S. The Potential of a Museum-School Partnership to Support Diversity and Multiliteracies-Based Pedagogy for the 21st Century. 2016. Vol. 111, № 4. P. 1840–1848.
Hillmen P. et al. Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria // N. Engl. J. Med. 2004. Vol. 350, № 6. P. 552–559.
Reiss U.M. et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria // Pediatr. Blood Cancer. Pediatr Blood Cancer, 2014. Vol. 61, № 9. P. 1544–1550.
McNamara L.A. et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine // MMWR. Morb. Mortal. Wkly. Rep. 2017. Vol. 66, № 27. P. 734–737.
Brodsky R.A. Stem cell transplantation for paroxysmal nocturnal hemoglobinuria. 2010. Vol. 95, № 6. P. 855–856.
de Latour R.P. et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria // Haematologica. 2012. Vol. 97, № 11. P. 1666–1673.
SHASHELEVA D.A. et al. Hematopoietic stem cell transplantation with alpha/beta T-lymphocyte depletion and short course of eculizumab in adolescents and young adults with paroxysmal nocturnal hemoglobinuria // Ter. Arkh. 2018. Vol. 90, № 7. P. 57–64.
Young N.S. et al. The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment and New Hope for Patients // Semin. Hematol. W.B. Saunders, 2009. Vol. 46, № SUPPL. 1.
Brecher M., Taswell H. Paroxysmal nocturnal hemoglobinuria and the transfusion of washed red cells. A myth revisited // Transfusion. 1989. Vol. 29, № 8. P. 681–685.
Parker C. Diagnosis and management of paroxysmal nocturnal hemoglobinuria // Blood. 2005. Vol. 106, № 12. P. 3699–3709.
Ayuk F., Balduzzi A. Donor Selection for Adults and Pediatrics // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies / ed. Carreras E. et al. Springer, 2019. P. 87–99.
Carreras E., Rambaldi A. Evaluation and Counseling of Candidates // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 77–87.
Confer D.L., Miller J.P., Chell J.W. Bone Marrow and Peripheral Blood Cell Donors and Donor Registries // Thomas’ Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 1–2. P. 423–432.
Witt V., Peters C. Collection of HSC in Children // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 123–127.
Gorin N.C. Bone Marrow Harvesting for HSCT // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 109–117.
Hübel K. Mobilization and Collection of HSC // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 117–123.
Querol S., Rocha V. Procurement and Management of Cord Blood // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 131–137.
Wuchter P. Processing, Cryopreserving and Controlling the Quality of HSCs // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 127–131.
Schumm M., Lang P., Handgretinger R. Graft Manipulation // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 137–143.
Nagler A., Shimoni A. Conditioning // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 99–109.
Danylesko I., Shimoni A., Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike // Bone Marrow Transplant. 2012 471. Nature Publishing Group, 2011. Vol. 47, № 1. P. 5–14.
Ruutu T. How to use busulfan in conditioning for allogeneic transplantation // Cell. Ther. Transplant. Universitatsklinikum Hamburg - Eppendorf, 2018. Vol. 7, № 1. P. 18–20.
Langenhorst J.B. et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation // Clin. Pharmacokinet. Springer, 2019. Vol. 58, № 5. P. 627.
Yoshida N. et al. Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide // Bone Marrow Transplant. 2020 557. Nature Publishing Group, 2020. Vol. 55, № 7. P. 1272–1281.
Penack O. et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation // The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, № 2. P. e157–e167.
Michonneau D., Socié G. GVHD Prophylaxis (Immunosuppression) // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 177–183.
Watanabe N. et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children // Bone Marrow Transplant. 2010 457. Nature Publishing Group, 2009. Vol. 45, № 7. P. 1161–1166.
Jacoby E. et al. Single agent post-transplantation cyclophosphamide as GVHD prophylaxis after HLA-matched related BMT for pediatric and young adult patients with hematologic malignancies // Biol. Blood Marrow Transplant. NIH Public Access, 2016. Vol. 22, № 1. P. 112.
Baron F. et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation // Haematologica. Ferrata Storti Foundation, 2017. Vol. 102, № 2. P. 224.
Koreth J. et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results // Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, № 3. P. 522–530.
Wertheimer T. et al. Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis // Ann. Hematol. 2021. Vol. 100, № 3. P. 779–787.
Drobyski W.R. et al. Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease // Biol. Blood Marrow Transplant. Elsevier, 2011. Vol. 17, № 12. P. 1862–1868.
Abouelnasr A. et al. Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment // Biol. Blood Marrow Transplant. 2013. Vol. 19. P. 12–21.
Schäfer H. et al. A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT // Ann. Hematol. 2021 1008. Springer, 2021. Vol. 100, № 8. P. 2095–2103.
Malard F. et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study // Blood. Content Repository Only!, 2017. Vol. 130, № 20. P. 2186–2195.
Cutler C., Antin J.H. Manifestations and Treatment of Acute Graft-versus-Host Disease // Thomas’ Hematopoietic Cell Transplantation. Chichester, UK: John Wiley & Sons, Ltd, 2016. Vol. 2–2. P. 1012–1025.
Holler E., Greinix H., Zeiser R. Acute Graft-Versus-Host Disease // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 323–330.
Toubai T., Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease // Blood. American Society of Hematology, 2020. Vol. 136, № 4. P. 429–440.
Martin P.J. How I treat steroid-refractory acute graft-versus-host disease // Blood. American Society of Hematology, 2020. Vol. 135, № 19. P. 1630–1638.
Nassar A. et al. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation // J. Transplant. Hindawi Limited, 2014. Vol. 2014. P. 1–10.
Kawashima N. et al. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan // Int. J. Hematol. 2019 1094. Springer, 2019. Vol. 109, № 4. P. 491–498.
Khandelwal P. et al. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients // Pediatr. Transplant. Pediatr Transplant, 2014. Vol. 18, № 1. P. 94–102.
Vicent M.G. et al. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results // Am. J. Hematol. John Wiley & Sons, Ltd, 2019. Vol. 94, № 3. P. 319–326.
Faraci M. et al. Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients // Biol. Blood Marrow Transplant. Elsevier, 2019. Vol. 25, № 4. P. 743–748.
Sleight B.S. et al. Infliximab for GVHD therapy in children // Bone Marrow Transplant. 2007 405. Nature Publishing Group, 2007. Vol. 40, № 5. P. 473–480.
Albert M.H. et al. Oral graft vs. host disease in children - Treatment with topical tacrolimus ointment // Pediatr. Transplant. Pediatr Transplant, 2007. Vol. 11, № 3. P. 306–309.
Zangrilli A. et al. Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus // Pediatr. Int. Pediatr Int, 2010. Vol. 52, № 3. P. e161-3.
Baird K. et al. Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease // Biol. Blood Marrow Transplant. Biol Blood Marrow Transplant, 2015. Vol. 21, № 6. P. 1083–1090.
Wolff D., Lawitschka A. Chronic Graft-Versus-Host Disease // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 331–347.
Filipovich A.H. et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report // Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 2005. Vol. 11, № 12. P. 945–956.
Jagasia M.H. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report // Biol. Blood Marrow Transplant. Elsevier Inc., 2015. Vol. 21, № 3. P. 389-401.e1.
Mikulska M. Infection Control and Isolation Procedures // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 189–197.
Mikulska M. Neutropenic Fever // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 259–265.
Ljungman P., Styczynski J., Einsele H. Viral Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 281–291.
Maertens J.A. Invasive Fungal Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 273–281.
Groll A.H. et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation // The Lancet Oncology. Lancet Publishing Group, 2014. Vol. 15, № 8.
Cesaro S. Haemorrhagic Cystitis and Renal Dysfunction // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 387–393.
Carreras E., Diaz-Ricart M. Early Complications of Endothelial Origin // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 315–323.
Mahadeo K.M. et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement // The Lancet Haematology. Elsevier Ltd, 2020. Vol. 7, № 1. P. e61–e72.
Sung L. et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation // BMJ Supportive and Palliative Care. BMJ Publishing Group, 2017. Vol. 7, № 1. P. 7–16.
Ghali M.G.Z. et al. Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management // Leukemia and Lymphoma. Taylor and Francis Ltd, 2019. Vol. 60, № 10. P. 2365–2372.
Cooke K.R. Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again // Pediatr. Transplant. John Wiley & Sons, Ltd, 2005. Vol. 9, № SUPPL. 7. P. 25–36.
Jodele S. et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy // Transfusion and Apheresis Science. Elsevier Ltd, 2016. Vol. 54, № 2. P. 181–190.
Baumgartner A., Schuetz P. Nutritional Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 171–177.
Schrezenmeier H. et al. Transfusion Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 163–171.
Bahar B., Tormey C.A. Prevention of transfusion-associated graft-versus-host disease with blood product irradiation the past, present, and future // Archives of Pathology and Laboratory Medicine. College of American Pathologists, 2018. Vol. 142, № 5. P. 662–667.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница

Приложение А3. Справочные материалы, включая соответствие показаний к применению и противопоказаний, способов применения и доз лекарственных препаратов, инструкции по применению лекарственного препарата +

Приложение Б. Алгоритмы действий врача

Приложение В. Информация для пациента

Данный блок поддерживает скрол*